 CAMBRIDGE, Mass., Oct. 20, 2022 GLOBE NEWSWIRE -- Foghorn Therapeutics Inc. Nasdaq: FHTX, a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the Company will present new data at Hanson Wades 5th Annual Targeted Protein Degradation Summit. The Summit will be held in Danvers, Mass., on October 2528, 2022. Foghorn is advancing its protein degradation platform and pipeline which includes FHD-609, a first-in-class, highly potent, and selective degrader of BRD9, for the treatment of synovial sarcoma and SMARCB1-loss tumors, and additional programs. 